TOKYO, May 15 (Pulse News Wire) – Linical CO.,LTD. (2183.T) reported impairment losses totaling ¥1.1 billion for its fiscal year ending March 31, 2026.
The company recorded ¥700 million in impairment loss related to fixed assets in its Japanese operations and ¥400 million in goodwill impairment loss in its European operations. Additionally, individual decision-making resulted in a further ¥300 million in impairment loss for fixed assets. In conjunction with these impairments, Linical also recognized a significant decline in the fair value of its investment in LINICAL Europe Holding GmbH, leading to a special loss of ¥200 million in its individual financial statements. However, this did not impact the consolidated results due to offsetting entries.
Regarding the difference between forecasted and actual performance for the fiscal year, Linical’s revenue, operating profit, and ordinary profit showed slight improvements compared to previous forecasts, primarily driven by cost-cutting measures. Despite these gains, net income attributable to parent shareholders fell below expectations due to the aforementioned impairment charges. Specifically, the company revised its earnings per share from the previously estimated ¥24.52 to ¥64.41. For detailed figures, investors should refer to the “Consolidated Financial Results Briefing for the Fiscal Year Ending March 31, 2026” released today.
🟢 Confidence: High AI-translated content.